Researchers at the University of Bern and University Hospital Bern have achieved a breakthrough in a particularly aggressive form of prostate cancer. In tissue samples from advanced brain metastases, they were able to establish ...
May 12, 2022
0
70
Results from early-stage clinical trials show two drugs that target the DNA damage response (DDR) pathway in cancers—ATR inhibitor elimusertib and PARP inhibitor AZD5305—are safe and clinically beneficial in treating ...
Apr 11, 2022
0
4
The results from the major phase III OlympiA trial shows the drug improves survival rates in women who have inherited faults in their BRCA1 or BRCA2 genes.
Mar 17, 2022
0
23
The clinical trial of an old antibiotic for a new purpose is offering hope to thousands of patients with drug-resistant breast cancer whose early remissions have given way to resurgent tumors.
Mar 15, 2022
0
3
Scientists have revealed how cancer can resist PARP inhibitors, a precision medicine used to treat thousands of patients worldwide.
Jan 11, 2022
0
64
A new study led by University of California, Irvine researchers has confirmed a link between altered DNA repair and increased DNA damage associated with spinocerebellar ataxia type 7 (SCA7), a debilitating, sometimes deadly ...
Nov 30, 2021
0
26
A potential new drug candidate developed by researchers at the University of Oulu, Finland, has been granted a patent in the United States. The drug is a small molecular chemical compound that is especially suited for cancer ...
Nov 8, 2021
0
7
Talazoparib, a new precision drug, can keep cancer in check in some men with advanced prostate cancer who have run out of options, a phase II clinical trial shows.
Aug 23, 2021
0
129
A team of Massachusetts General Hospital (MGH) researchers has discovered how an important class of anti-cancer drugs called PARP inhibitors works, a finding that could help improve treatment and prolong survival for patients ...
Aug 12, 2021
0
247
Drugs that target specific proteins have greatly improved patient outcomes across a broad range of tumor types; however, patients often develop drug resistance and tumor recurrence. There is a great unmet need to identify ...
Jul 29, 2021
0
36
